Sign In

July 20, 2017
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.
July 18, 2017
Recent guidelines are right to recommend screening high risk patients for cirrhosis, say liver specialists Mark Hudson at Freeman Hospital, Newcastle upon Tyne, and Nick Sheron at Southampton General...
July 13, 2017
A new study has revealed that bile duct cells can switch to become normal liver cells to help repair the liver after severe damage.
July 12, 2017
A new study in The American Journal of Pathology reports that mice fed a Western diet, which is high in fat and sugar, resulted in hepatic inflammation, especially in males.
July 4, 2017
New findings from mouse models reveal that the type of immune response that helps maintain healthy metabolism in fatty tissues, called type 2 immunity, also drives obesity-induced nonalcoholic fatty...
July 4, 2017
Cambridge scientists have developed a new method for growing and transplanting artificial bile ducts that could in future be used to help treat liver disease in children, reducing the need for liver...
July 4, 2017
For patients with colorectal cancer that has metastasized to the liver, having a primary tumour on the left side, as opposed to the right side of the colon, is known to be a significant advantage in...
June 30, 2017

Alexandria, VA – The American Association for the Study of Liver Diseases Foundation, the largest private supporter of liver disease research and training in the United States, today announced its investment of $3.34 million in research and career development funding granted to 25 researchers and clinicians to conduct innovative liver disease research and seek advanced hepatology training.

June 26, 2017
Scientists from the University of Birmingham have discovered the link between increased male hormones and metabolic complications such as diabetes and fatty liver disease in patients with polycystic...
June 22, 2017

AASLD and IDSA have serious concerns regarding the recent Cochrane Group Review of DAAs.

Pages